Linda Yaccarino, former CEO of X Corp., has taken the CEO position at eMed Population Health, a telehealth company specializing in GLP-1 weight loss drugs, after leaving X. Despite lacking health sector experience, she brings expertise in brand partnerships and digital revenue growth, aiming to transform the obesity and diabetes treatment market through innovative digital care solutions.
Linda Yaccarino, former CEO of X, has been appointed as the CEO of eMed Population Health, an AI startup focusing on health technology related to GLP-1 drugs for weight management and diabetes, leveraging her negotiation skills and tech industry recognition to lead the company's efforts to improve global healthcare outcomes.
Linda Yaccarino, former X social media executive, has become CEO of eMed, a telehealth company shifting focus to GLP-1 weight-loss drugs after struggling with Covid testing services, as she moves from one challenging role to another.